Brief: AlloVir Presents Final Results From Phase 2 Trial Of Posoleucel Treatment At ATC 2023

Kalaris Therapeutics

05/06/2023 13:15

June 5 (Reuters) - AlloVir Inc  ALVR.O :
    * ALLOVIR PRESENTS POSITIVE FINAL RESULTS FROM A PHASE 2
RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING POSOLEUCEL
TREATMENT OF BK INFECTION IN KIDNEY TRANSPLANT RECIPIENTS AT THE
AMERICAN TRANSPLANT CONGRESS (ATC 2023)
    * ALLOVIR INC - POSOLEUCEL DEMONSTRATED CLINICALLY
MEANINGFUL
REDUCTIONS IN BK VIRAL LOAD AS COMPARED TO PLACEBO
    * ALLOVIR INC - REPEAT ADMINISTRATION OF POSOLEUCEL WAS
GENERALLY
WELL TOLERATED, WITH BALANCED SAFETY ACROSS POSOLEUCEL DOSING
GROUPS AND PLACEBO

Source text for Eikon:  ID:nBw5S1LCHa 
Further company coverage:  ALVR.O 

 ((Reuters.Briefs@thomsonreuters.com))